Jun 16, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
SCYNEXIS Presents In Vitro Toxicity Study Suggesting That SCY-635 Is Unique In The Cy
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2140134" data-attributes="member: 124445"><p>Drug discovery company SCYNEXIS, Inc. today presented results from two separate studies of SCY-635-a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection-at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. The first presentation outlined results from an in vitro study demonstrating that, unlike other cyclophilin inhibitors, SCY-635 is not associated with an increased risk of hyperbilirubinemia in 15-day clinical studies...<a href="http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/dda830zQ3uM" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/dda830zQ3uM/3Brv" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2140134, member: 124445"] Drug discovery company SCYNEXIS, Inc. today presented results from two separate studies of SCY-635-a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection-at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. The first presentation outlined results from an in vitro study demonstrating that, unlike other cyclophilin inhibitors, SCY-635 is not associated with an increased risk of hyperbilirubinemia in 15-day clinical studies...[URL="http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/0/da"][IMG]http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/1/da"][IMG]http://feedads.g.doubleclick.net/~a/pzmRdPaJflbdPvr7WxIXSW6jz4M/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/dda830zQ3uM[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/dda830zQ3uM/3Brv]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top